CLINUVEL PHARMACEUTICALS/ AU000000CUV3 /
2024-04-26 7:02:59 PM | Chg. -0.1050 | Volume | Bid7:03:00 PM | Ask7:03:00 PM | High | Low |
---|---|---|---|---|---|---|
8.9450EUR | -1.16% | 670 Turnover: 6,016.1500 |
-Bid Size: - | -Ask Size: - | 9.0000 | 8.8850 |
GlobeNewswire
03-28
Photomedicine Pioneer CLINUVEL Unveils Clinical, Cosmetic Ambitions to German Investors
GlobeNewswire
2018-12-19
Phase II study: SCENESSE® in combination with narrowband ultraviolet B (NB-UVB) achieves repigmentat...
GlobeNewswire
2018-06-25
FDA to Review Australian Drug for Genetic Disorder of Absolute Light Intolerance
GlobeNewswire
2017-04-12
CLINUVEL reaches agreement on German SCENESSE® pricing through AMNOG Arbitration Board
GlobeNewswire
2016-06-01
Nasdaq Welcomes Additional Companies to the Nasdaq International Designation